Pembrolizumab, a humanized immunoglobulin monoclonal antibody directed against the programmed cell death 1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials.
Aim:
To investigate the efficacy and safety of first-line pembrolizumab for patients with non-small cell lung cancers (NSCLCs) in clinical practice.
Methods:
In this observational monocentric retrospective study, 38 patients with PD-L1 >50% were enrolled between November 2017 and November 2018.
Results:
The global median overall survival was 11.08 months (95% confidence interval [CI], 5.98–not reached) and the global median progression-free survival was 6 months (95% CI, 3–not reached). In the univariate analysis, clinical performance status score and the development of immune-related adverse events were the only 2 clinical factors significantly correlated with overall survival.
Conclusion:
The results of the present study suggest that pembrolizumab seems less effective in the real-life population than in the pivotal clinical trials in patients with NSCLC but remains an effective treatment option for patients with NSCLC. Longer follow-up is needed.
KawanoYOhyanagiFYanagitaniN, et al. Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study. Anticancer Res2013; 33: 3327–3333.
2.
BreathnachOSFreidlinBConleyB, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol2001; 19: 1734–1742.
3.
LuTYangXHuangY, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res2019; 11: 943–953.
4.
WangSSunTSunH, et al. Survival improvement in patients with non-small cell lung cancer between 1983 and 2012: analysis of the Surveillance, Epidemiology, and End Results database. Tumour Biol2017; 39: 101042831769167.
ZappaCMousaSA.Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res2016; 5: 288–300.
7.
MascauxCTomasiniPGreillierL, et al. Personalised medicine for non-small cell lung cancer. Eur Respir Rev2017; 26: 170066.
8.
PardollDM.The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer2012; 12: 252–264.
9.
BiancoAMalapelleURoccoD, et al. Targeting immune checkpoints in non-small cell lung cancer. Curr Opin Pharmacol2018; 40: 46–50.
10.
ChenSSongZZhangA.Small-molecule immuno-oncology therapy: advances, challenges and new directions. Curr Top Med Chem2019; 19: 180–185.
11.
BellmuntJde WitRVaughnDJ, et al, KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med2017; 376: 1015–1026.
12.
RiniBIPlimackERStusV, et al, KEYNOTE-426 Investigateurs. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med2019; 380: 1116–1127.
13.
VargaAPiha-PaulSOttPA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol2019; 152: 243–250.
14.
CohenEEWSoulièresDLe TourneauC, et al, KEYNOTE-040 Investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet2019; 393: 156–167.
15.
CarlinoMSLongGVSchadendorfD, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial. Eur J Cancer2018; 101: 236–243.
16.
ShitaraKÖzgüroğluMBangYJ, et al, KEYNOTE-061 Investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet2018; 392: 123–133.
17.
ZhuAXFinnRSEdelineJ, et al, KEYNOTE-224 Investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol2018; 19: 940–952.
18.
ReckMRodríguez-AbreuDRobinsonAG, et al, KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med2016; 375: 1823–1833.
19.
BrahmerJRRodríguez-AbreuDRobinsonAG, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol2017; 18: 1600–1609.
20.
ReckMRodríguez-AbreuDRobinsonAG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol2019; 37: 537–546.
21.
KhozinSCarsonKRZhiJ, et al. Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval. Oncologist2019; 24: 648–656.
22.
CortelliniAChiariRRicciutiB, et al. correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer2019; 20: 237–247.
23.
HodiSFBallingerMLyonsB, et al. Immune modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol2018; 36: 850–858.
24.
VelchetiVChandwaniSChenX, et al. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy2019; 11: 889–901.
25.
Cuyún CarterGBarrettAMKayeJA, et al. Comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res2014; 6: 437–449.
26.
PengTRWuTW.Real-world experience with pembrolizumab in patients with advanced lung cancer. Am J Ther2019; 26: e537–e538.
27.
SatoKAkamatsuHMurakamiE, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer2018; 115: 71–74.
28.
RogadoJSánchez-TorresJMRomero-LaordenN, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer2019; 109: 21–27.
29.
CoweyCLLiuFXBlack-ShinnJ, et al. Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices. J Immunother2018; 41: 86–95.
30.
MokTSKWuYLKudabaI, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet2019; 393: 1819–1830.
31.
SoACBoardRE.Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK. Melanoma Manag2018; 5: MMT05.
32.
KsienskiDWaiESCroteauN, et al. Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice. Lung Cancer2019; 133: 110–116.
33.
JansenYSchreuerMNeynsB.Single-center ‘real life experience’ with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients. J Clin Oncol2016; 34: e21049.
34.
LomaxALimJChengR, et al. Metastatic melanoma and pembrolizumab toxicity in a real-world setting: practical management of common toxicities. Asia-Pac J Clin Oncol2016; 12: 60.
